NORMA: Norwegian Microbiota Study in Anorexia Nervosa

Sponsor
Norwegian University of Life Sciences (Other)
Overall Status
Recruiting
CT.gov ID
NCT06144905
Collaborator
Oslo University Hospital (Other), Helse Nord-Trøndelag HF (Other), Haukeland University Hospital (Other), Nordlandssykehuset HF (Other), Modum Bad (Other), Karolinska Institutet (Other), The Eating disorder Association, Norway (SPISFO) (Other), Counseling on eating disorders, Norway (ROS) (Other)
180
1
239.2
0.8

Study Details

Study Description

Brief Summary

Anorexia nervosa (AN) is a serious mental disorder occurring mainly in women. AN is characterized by severely restricted food-intake and subsequent low weight. The disease burden for the individual is high with medical complications and psychiatric comorbidities. Despite decades of research, there are large gaps in the understanding of the biological aspects of AN and lack of effective interventions. Current clinical treatment is associated with gastrointestinal problems, high rates of relapse and poor outcome causing long-term sickness absence and disability. During the COVID19 pandemic the prevalence and severity of AN has spiked. Therefore, there is great need of novel strategies for AN treatment, that can be easily implemented in the clinic without adding complexity to the standard care of treatment. During the resent years it has been proposed that mental disorders might be treated via manipulating the composition and function of the microbes that live in the gut (the microbiota) by adding or restricting fermentable nutrients (prebiotics) in the diet. However, in order to use prebiotics to treat the microbiota in AN patients, more knowledge is needed on how the AN microbiota is affected by the current standard care treatment. Whether prebiotics can be useful for normalizing AN microbiota remains to be established. The overall aim of the "Norwegian study of Microbiota in Anorexia Nervosa" (NORMA) is to join forces of researchers, clinical health care services and voluntary sector in a transdiciplinary approach to improve the understanding of the role of the gut microbiota in AN patients. The current project will include a clinical trial in AN patients and experimental studies to screen novel prebiotics for their ability to modify and normalize AN derived microbiota. The long-term goal of the project is to pave the way for a targeted and clinically feasible individualized treatment for better tolerable weight-restoration and improved health in AN patients.

Condition or Disease Intervention/Treatment Phase
  • Other: standard care treatment program

Study Design

Study Type:
Observational
Anticipated Enrollment :
180 participants
Observational Model:
Cohort
Time Perspective:
Cross-Sectional
Official Title:
Gut Microbiota Alterations in Anorexia Nervosa - Paving the Way for Personalized Prebiotic Treatment Strategies
Actual Study Start Date :
Sep 24, 2023
Anticipated Primary Completion Date :
Sep 1, 2025
Anticipated Study Completion Date :
Sep 1, 2043

Arms and Interventions

Arm Intervention/Treatment
Anorexia nervosa (AN) group

Female in-patients with anorexia nervosa, age 16-50 years with BMI below 18.5 kg/m2.

Other: standard care treatment program
The standard care treatment consists of a program of psychotherapy and nutritional rehabilitation to achieve normalization of food-intake and weight gain.

Heathy control (HC) group

Female healthy controls, age 16-50 with normal to mild overweight (18.5 ≤ BMI< 27 kg/m2). .

Outcome Measures

Primary Outcome Measures

  1. Differences in the fecal microbiota composition [Cross-sectional study with only one time point. For AN-group; the baseline sample is delivered during the last week before start of clinical treatment. ]]

    Comparison of fecal microbial composition between the patients with anorexia nervosa and healthy controls. We will compare different indices of α-diversity - investigating both richness and evenness (e.g. observed number of OTUs, Chao1, Shannon-Wiener, Simpson, and PD whole tree) and different indices of β-diversity (e.g. binary Jaccard, Bray-Curtis, and weighted Unifrac). Also differences in bacterial abundances at various taxonomic levels (phylum, class, order, family, and genus) will be investigated.

  2. Change in the fecal microbiota composition in patients with anorexia nervosa during the standard care treatment at the clinics for eating disorder. [One group time-series design. Samples will be taken at baseline (~one week before admission to the clinic) and at ~6 weeks and ~12 weeks.]

    Mixed model analyses will be performed to assess whether the standard care treatment at the clinics for eating disorder induce changes in the fecal microbiota composition. Both diversity measures ( α-diversity and β-diversity) and bacterial abundances at various taxonomic levels (phylum, class, order, family, and genus) will be investigated.

  3. Change in mental scores during standard care treatment at the clinics for eating disorder [One group time-series design. Data will be collected at baseline, at admission to the clinic and at ~6 weeks and ~12 weeks.]

    Mixed model analyses will be performed to assess whether the standard care treatment at the clinics for eating disorder induce changes in mental scores. Effects of time will be investigated in the AN group only. Mental scores will be assessed using digital questionnaires.

  4. Change in gastrointestinal problems during standard care treatment at the clinics for eating disorder [One group time-series design. Data will be collected at baseline, at admission to the clinic and at ~6 weeks and ~12 weeks.]

    Mixed model analyses will be performed to assess whether the standard care treatment at the clinics for eating disorder induce changes in gastrointestinal problems. Effects of time will be investigated in the AN group only. Scores for gastrointestinal problems will be assessed using digital questionnaires.

Secondary Outcome Measures

  1. Associations between microbiota measures (diversity and abundance of specific species), serum biomarkers, dietary charachteristics, gastrointestinal issues and mental issues. [Cross-sectional study with only one time point. For AN-group; the baseline sample is delivered during the last week before start of clinical treatment. ]]

    Associations between multiple variables will be investigated in both AN group (at baseline, 6 weeks and 12 weeks) and HC group at baseline using unsupervised learning algorithm techniques such as Principal Component Analysis and hireachical clustering techniques. Microbiota is charachterized as described under outcome 1, serum biomarkers include standard clinical biomarkers and biomarkers of inflammation and microbiota relevant biomarkers. Data on dietary charachteristics, gastrointestinal issues and mental issues are obtained by digital questionnaires.

  2. Associations between baseline microbiota composition and changes in gastrointestinal complaints during the standard care treatment at the clinics for eating disorder. [One group time-series design. Samples, data will be obtained at baseline (~one week before admission to the clinic) and at ~6 weeks and ~12 weeks.]

    Associations between microbiota measures at baseline and changes in gastrointestinal complaint sduring the standard care treatment at the clinics for eating disorder will be investigated by unsupervised learning algorithm techniques such as Principal Component Analysis and by applying hireachical clustering techniques on correlation measures. Microbiota will be charachterized as described under outcome 1, serum biomarkers include standard clinical biomarkers and biomarkers of inflammation and microbiota relevant biomarkers. Data on dietary charachteristics, gastrointestinal issues and mental issues are obtained by digital questionnaires.

  3. Associations between baseline microbiota composition and changes in mental scores during the standard care treatment at the clinics for eating disorder. [One group time-series design. Samples, data will be obtained at baseline (~one week before admission to the clinic) and at ~6 weeks and ~12 weeks.]

    Associations between microbiota measures at baseline and changes in mental scores during the standard care treatment at the clinics for eating disorder will be investigated by unsupervised learning algorithm techniques such as Principal Component Analysis and by applying hireachical clustering techniques on correlation measures. Microbiota will be charachterized as described under outcome 1, serum biomarkers include standard clinical biomarkers and biomarkers of inflammation and microbiota relevant biomarkers. Data on dietary charachteristics, gastrointestinal issues and mental issues are obtained by digital questionnaires.

Eligibility Criteria

Criteria

Ages Eligible for Study:
16 Years to 50 Years
Sexes Eligible for Study:
Female

Inclusion Criteria AN group

  1. Sex: Female

  2. Age: 16-50 years

  3. BMI: <18.5 kg/m2

  4. fulfilling ICD-10 criteria for AN

  5. currently referred to specialized inpatient nutritional treatment for AN

  6. able to understand the Norwegian questionnaires.

Exclusion Criteria AND group:
  1. history of inflammatory bowel disease, celiac disease, or GI tract surgery;

  2. treatment with oral antibiotics the past two months

  3. high intake of probiotic supplements over the past two months.

Inclusion criteria control group

  1. Sex: Female

  2. Age: 16-50 years

  3. BMI: >= 18.5 & < 27

  4. able to understand the Norwegian questionnaires.

Exclusion Criteria AND group:
  1. history of inflammatory bowel disease, celiac disease, or GI tract surgery;

  2. treatment with oral antibiotics the past two months

  3. high intake of probiotic supplements over the past two months.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Norwegian University of Life Sciences Ås Norway 1433

Sponsors and Collaborators

  • Norwegian University of Life Sciences
  • Oslo University Hospital
  • Helse Nord-Trøndelag HF
  • Haukeland University Hospital
  • Nordlandssykehuset HF
  • Modum Bad
  • Karolinska Institutet
  • The Eating disorder Association, Norway (SPISFO)
  • Counseling on eating disorders, Norway (ROS)

Investigators

  • Principal Investigator: Siv K Bøhn, PhD, Norwegian University of Life Sciences

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Siv K Bohn, Professor, Norwegian University of Life Sciences
ClinicalTrials.gov Identifier:
NCT06144905
Other Study ID Numbers:
  • 336239_KBM_SKB2023
First Posted:
Nov 22, 2023
Last Update Posted:
Nov 22, 2023
Last Verified:
Nov 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 22, 2023